Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer

BACKGROUND: Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES). METHODS: Castration-resistant prostate cancer patients treated with abiraterone w...

Descripción completa

Detalles Bibliográficos
Autores principales: Omlin, A, J Pezaro, C, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778298/
https://www.ncbi.nlm.nih.gov/pubmed/23928659
http://dx.doi.org/10.1038/bjc.2013.446
_version_ 1782285090680733696
author Omlin, A
J Pezaro, C
Zaidi, S
Lorente, D
Mukherji, D
Bianchini, D
Ferraldeschi, R
Sandhu, S
Dearnaley, D
Parker, C
Van As, N
de Bono, J S
Attard, G
author_facet Omlin, A
J Pezaro, C
Zaidi, S
Lorente, D
Mukherji, D
Bianchini, D
Ferraldeschi, R
Sandhu, S
Dearnaley, D
Parker, C
Van As, N
de Bono, J S
Attard, G
author_sort Omlin, A
collection PubMed
description BACKGROUND: Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES). METHODS: Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded. RESULTS: Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ⩾50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ⩾50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES. CONCLUSION: Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
format Online
Article
Text
id pubmed-3778298
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-37782982014-09-03 Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer Omlin, A J Pezaro, C Zaidi, S Lorente, D Mukherji, D Bianchini, D Ferraldeschi, R Sandhu, S Dearnaley, D Parker, C Van As, N de Bono, J S Attard, G Br J Cancer Short Communication BACKGROUND: Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES). METHODS: Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded. RESULTS: Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ⩾50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ⩾50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES. CONCLUSION: Abiraterone has important antitumour activity in men with CRPC even after DES exposure. Nature Publishing Group 2013-09-03 2013-08-08 /pmc/articles/PMC3778298/ /pubmed/23928659 http://dx.doi.org/10.1038/bjc.2013.446 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Short Communication
Omlin, A
J Pezaro, C
Zaidi, S
Lorente, D
Mukherji, D
Bianchini, D
Ferraldeschi, R
Sandhu, S
Dearnaley, D
Parker, C
Van As, N
de Bono, J S
Attard, G
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
title Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
title_full Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
title_fullStr Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
title_full_unstemmed Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
title_short Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
title_sort antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778298/
https://www.ncbi.nlm.nih.gov/pubmed/23928659
http://dx.doi.org/10.1038/bjc.2013.446
work_keys_str_mv AT omlina antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT jpezaroc antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT zaidis antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT lorented antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT mukherjid antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT bianchinid antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT ferraldeschir antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT sandhus antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT dearnaleyd antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT parkerc antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT vanasn antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT debonojs antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer
AT attardg antitumouractivityofabirateroneanddiethylstilboestrolwhenadministeredsequentiallytomenwithcastrationresistantprostatecancer

Ejemplares similares